Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Trump Administration to Secure Equity Stake in Pat Gelsinger’s XLight Startup 
China Urged to Prioritize Economy Over Territorial Ambitions, Says Taiwan’s President Lai 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Oil Prices Rise as Ukraine Targets Russian Energy Infrastructure 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Asian Currencies Steady as Rupee Hits Record Low Amid Fed Rate Cut Bets 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
U.S. Futures Steady as Rate-Cut Bets Rise on Soft Labor Data 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
European Stocks Rise as Markets Await Key U.S. Inflation Data 
Asian Markets Stabilize as Wall Street Rebounds and Rate Concerns Ease 
Magnum Audit Flags Governance Issues at Ben & Jerry’s Foundation Ahead of Spin-Off 
Celltrion has completed the third phase of its COVID-19 drug testing after administering the experimental coronavirus antibody treatment to 1,300 individuals who participated in this stage of the clinical trial.
The COVID-19 drug under trial
As per The Korea Herald, this phase 3 is the final step in the human tests of the medicine that was named Regkirona or CT-P59. It was mentioned that the trials are being done in 13 nations that include the U.S., South Korea, Romania, and Spain.
Based on the report, the said drug has been approved in Korea for emergency use and was issued an authorization in February. It was then used to treat patients with mild symptoms in adults and those belonging to high-risk groups. Celltrion shared that they did not find any unusual reaction from a group of patients who received the drug.
The next step for the Korean biopharmaceutical company based in Incheon is to gather the results of the tests and forward them to overseas and local health authorities. Celltrion may do this within the last week of June this year.
“Celltrion has secured enough patients for phase 3 clinical study and expects to speed up discussions to export the COVID-19 antibody treatment,” a company official said. “We will focus on successfully completing the phase 3 clinical trial by the first half this year.”
The company is said to have already produced enough doses of the tested drug for 100,000 people. And once Celltrion secured all the necessary documents and approval for Regkirona, it has the capacity to produce the treatment for at least three million people per year.
Celltrion’s board welcomes the founders’ sons
Meanwhile, Celltrion founder Seo Jung Jin’s two sons have reportedly joined the company’s board of non-listed holding entities. The move was done to prepare for the second-generation management and generational shift. The sons’ entrance to Celltrion’s board also comes after Seo resigned last year.
Maeil Kyeongje News reported that the eldest son, Seo Jin Seok, will be taking the vacated seat of his father as the board chairman of Celltrion Holdings. He was also assigned as the head of the company’s managing board last month during a shareholder’s meeting.
Finally, Seo Joon Serk, the younger brother of Jin Seok, will be the board director of Celltrion Healthcare Holdings, the largest shareholder of Celltrion Healthcare that was established only last year.
